Subscribe to our newsletter.
Copyright 2024 © All rights Reserved Goffin Molecular Technologies
The 5-Gene-Multiplex 5% AF cfDNA in Plasma product by SensID is a critical tool for liquid biopsy assays in diagnostics and research. It targets five key mutations in the genes AKT1, BRAF, KRAS, PIK3CA, and ERBB2, which are crucial for diagnosing and treating cancers like lung, breast, and colorectal cancer, as well as melanoma.
This product has a 0.1% allelic frequency (AF) of the mutations and is used as a positive control in advanced applications such as digital PCR and next-generation sequencing (NGS). The 5-Gene-Multiplex 5% AF cfDNA in Plasma aids in optimizing sequencing and PCR protocols, setting detection limits, and ensuring accurate variant calling.
The targeted mutations include:
These mutations play a significant role in personalized cancer treatment, as they are linked to targeted therapies such as vemurafenib for BRAF, cetuximab for KRAS, and treatments for AKT1 and PIK3CA mutations. The 5-Gene-Multiplex 5% AF cfDNA in Plasma ensures accurate diagnostics and supports the development of better cancer therapies.
IFU
MSDS
For any missing information or if you require additional details, please do not hesitate to contact us.
The 5-Gene-Multiplex 5% AF cfDNA in Plasma product by SensID is a highly specialized tool designed for liquid biopsy assays, primarily used in diagnostic and research environments. This product targets key mutations in five essential genes: AKT1, BRAF, KRAS, PIK3CA, and ERBB2. These mutations are vital for diagnosing and treating various cancers such as lung, breast, colorectal cancer, and melanoma.
Containing a 0.1% allelic frequency (AF) of the specified mutations, the 5-Gene-Multiplex 5% AF cfDNA in Plasmaserves as a positive control standard for advanced applications like digital PCR (Polymerase Chain Reaction) and next-generation sequencing (NGS). This makes it an indispensable tool for validating and optimizing sequencing and PCR protocols, setting detection limits, and ensuring high-confidence variant calling in liquid biopsy workflows.
The targeted mutations include:
These mutations are crucial in clinical decision-making, as they are associated with targeted therapies. For instance, BRAF mutations are linked with vemurafenib treatment, KRAS mutations with cetuximab, and PIK3CA and AKT1 mutations with various targeted therapies. This makes the 5-Gene-Multiplex 5% AF cfDNA in Plasma product an essential tool for precise cancer treatment strategies.
By using the 5-Gene-Multiplex 5% AF cfDNA in Plasma, researchers and clinicians can confidently enhance the accuracy of their diagnostic assays, improve the reliability of their sequencing results, and develop better treatment protocols based on genetic data.
5-Gene-Multiplex 5% AF cfDNA in Plasma
Subscribe to our newsletter.